272 studies found for:    Expanded Access Studies
Show Display Options
Download search resultsDownload the search results for:
Expanded Access Studies (272 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Temporarily not available Expanded Access Protocol for an Intermediate Size Population - RAVICTI for Byler Disease
Condition: Byler Disease
Intervention: Drug: RAVICTI
2 Available Treatment Plan to Provide Expanded Access to Stiripentol for Patients With Dravet Syndrome
Condition: Dravet Syndrome
Intervention: Drug: Stiripentol
3 No longer available Immunosuppressive Medications for Participants in ITN005CT (NCT00014911)
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Sirolimus;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Mycophenolic acid
4 Available An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
Condition: Differentiated Thyroid Cancer
Intervention: Drug: Lenvatinib
5 No longer available Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP
Condition: Lambert Eaton Myasthenic Syndrome (LEMS)
Intervention: Drug: 3,4-diaminopyridine
6 No longer available Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute GVHD
Condition: Graft-Versus-Host Disease
Intervention: Drug: Prochymal®
7 Unknown  HIV-discordant Couple Intrauterine Insemination
Conditions: Infertility;   HIV Infections
Interventions: Other: Sperm washing and testing for HIV contamination;   Procedure: Intrauterine Insemination
8 No longer available Compassionate Use of Defibrotide for Patients With Veno-occlusive Disease of the Liver
Condition: Hepatic Veno-occlusive Disease
Intervention: Drug: Defibrotide
9 No longer available McKenzie Exercise Vs Harmonic Technique in Chronic Low Back Pain
Condition: Low Back Pain
Interventions: Behavioral: McKenzie exercise;   Device: Harmonic technique
10 Available Post Study Continuation of C7 for G1D
Conditions: Glut1 Deficiency Syndrome;   Glucose Transporter Type 1 Deficiency Syndrome
Intervention: Drug: Triheptanoin
11 No longer available Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: Regorafenib (BAY73-4506)
12 Approved for marketing Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Nilotinib
13 Approved for marketing An Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients With Lamivudine-Resistant Chronic Hepatitis B With Limited Treatment Options
Condition: Chronic Hepatitis B
Intervention: Drug: Adefovir Dipivoxil
14 No longer available Treatment Use Study for Advanced Melanoma.
Condition: Advanced Unresectable Melanoma
Intervention: Drug: CP-675,206
15 Approved for marketing An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Obinutuzumab;   Drug: Chlorambucil
16 No longer available Treatment Use of Generex Oral-lyn™ in Patients With Diabetes
Conditions: Type 1 Diabetes Mellitus;   Type 2 Diabetes Mellitus
Intervention: Drug: Buccal insulin spray
17 Unknown  Prospective Analysis and Comparison of Stress Echo to Real-Time Myocardial Contrast Stress Echo
Condition: Evaluation of Troponin I Levels
Intervention: Other: Dobutamine: Perflutren Lipid Microsphere
18 Unknown  To Evaluate Oral Phase Swallowing Function Using Submental Ultrasound
Condition: Dysphagia
Intervention: Procedure: Ultrasound
19 Available Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Anti-CTLA-4 Treatment-Naïve Subjects With Unresectable or Metastatic Melanoma (CheckMate 218)
Condition: Malignant Melanoma
Interventions: Drug: Nivolumab;   Drug: Ipilimumab
20 Available Treatment of Lambert-Eaton Syndrome With 3,4 DAP
Condition: Lambert Eaton Myasthenic Syndrome
Intervention: Drug: 3, 4 DAP

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years